Secondary outcomes
SECONDARY, SYNDROME, POSITIVE
Across secondary outcomes, the results generally followed a similar pattern (see Table Summary of key results for primary and secondary outcome variables
Abbreviations: CBD = cannabidiol; PANSS = Positive and Negative Syndrome Scale; PLA = placebo; PSI = Psychotomimetic States Inventory; THC = delta‐9‐tetrahydocannabinol; VAS = visual analogue scale.For ‘Happy’, adults had higher ratings than adolescents on ‘PLA’, but similar ratings on ‘THC’ and ‘THC + CBD’. Moreover, within adolescents, ratings during ‘THC’ and ‘THC + CBD’ were higher than ‘PLA’, but within adults ratings during ‘THC’ and ‘THC + CBD’ were lower than during ‘PLA’.For CBD plasma levels, this interaction was driven by higher CBD levels on ‘THC + CBD’ in adults compared to adolescents, but similar levels in adults and adolescents during ‘PLA’ or ‘THC’.Exceptions to this pattern included the following results. There were drug by age‐group interactions for ‘happy’ (across T1–T5; Figure For subjective effects over time, there was no drug by age group‐by‐time interactions for any secondary outcome (Tables 